Filing Details
- Accession Number:
- 0000903423-16-001320
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-10-26 17:49:47
- Reporting Period:
- 2016-10-24
- Filing Date:
- 2016-10-26
- Accepted Time:
- 2016-10-26 17:49:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | Pharmaceutical Preparations (2834) | X0 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1131399 | Plc Glaxosmithkline | 980 Great West Road Brentford, Middlesex, X0 TW8 9GS | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2016-10-24 | 2,942,560 | $0.00 | 2,942,560 | No | 4 | C | Indirect | See explanation of responses |
| Common Shares | Acquisiton | 2016-10-24 | 211,567 | $0.00 | 3,154,127 | No | 4 | C | Indirect | See explanation of responses |
| Common Shares | Acquisiton | 2016-10-24 | 66,500 | $14.00 | 3,220,627 | No | 4 | P | Indirect | See explanation of responses |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See explanation of responses |
| No | 4 | C | Indirect | See explanation of responses |
| No | 4 | P | Indirect | See explanation of responses |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Series A-3 Preferred Shares | Disposition | 2016-10-24 | 2,942,560 | $0.00 | 2,942,560 | $0.00 |
| Common Shares | Series B Preferred Shares | Disposition | 2016-10-24 | 211,567 | $0.00 | 211,567 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering.
- The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").
- On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering
- Not applicable.
Billionaire Hedge Funds
